• BIA Blog

Evolving Expectations – BIA Chief Medical Officer Summit 2018

The BIA Chief Medical Officer Summit was a new event held in early March aimed at supporting the skills required to be a CMO in an SME. Here, Dr Penny Ward, CMO of Karus Therapeutics, and vice-Chair of the BIA Science and Innovation Advisory Committee, takes a look at some of the highlights from the day.

CEO Update: Monday 23 April

It was great to see so many BIA members at the official opening of the Cell and Gene Therapy Catapult’s new GMP manufacturing centre in Stevenage today. The formalities were done by Business Secretary Greg Clark MP, and Science and Universities Minister Sam Gymiah MP, but what inspired me was the way in which UK SME engagement has been the hallmark of the project to this point. Initial collaborators Autolus, Cell Medica, AdaptImmune, Thermo Fisher Scientific as well as the Cell and Gene Therapy Catapult itself are BIA members so for me it’s fantastic to see the power of our community using the Industrial Strategy we’ve advocated to move this important part of our sector forward.

Video of the Week - Genomics Education Programme: Meet the Clinical Bioinformaticians

Clinical bioinformaticians work to make genome data clinically actionable; to make sense of large amounts of data so that other healthcare professionals can use it to inform decisions about diagnosis, treatment and care. They straddle the worlds of biology and computer programming to provide a vital link in the patient pathway. This film from the Genomics Education Programme showcases what the work of a clinical bioinformatician involves, the kind of traits and skills required, and some of the challenges facing both those working in the profession and the NHS more broadly.

The new high-speed drug discovery path using AI: Where soft IP meets hard IP to form a dynamic alliance – By Dr Eileen McMorrow

In this blog, Dr Eileen McMorrow, Senior Associate at Pennington Manches, explores some of the IP issues that may arise from the increasing utilisation of artificial intelligence in drug discovery.

April’s London Networking Breakfast

Last Wednesday, over 110 delegates from across the sector descended on the London offices of Herbert Smith Freehills for the latest BIA Networking Breakfast. Coinciding with World Parkinson’s Day 2018, the event was fittingly themed around exploring new patient-centric funding models for accelerating cures.

CEO Update: Monday 16 April

We kicked off last week with the release of our latest quarterly biotech financing update, produced with our data partner Informa Pharma Intelligence. The report, which looks at the sector’s finance data between December 2017 and February 2018, shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018. It’s great to see UK biotech companies starting the year with some strong fundraisings, including some great outcomes for BIA member companies such as Orchard Therapeutics and GW Pharma. We look forward to tracking the trends for UK biotech financing throughout these quarterly updates in 2018.

Video of the Week - #UniteForParkinsons

World Parkinson's Day was held earlier this week, on Wednesday 11th of April. This video shares the experiences of people living with Parkinson's from across the globe and shows how the disease affects their day-to-day life.

Uniting for Parkinson’s – how Parkinson’s UK and drug development companies are coming together to accelerate better treatments

All over the world, today (April 11th) is being recognised as World Parkinson’s Day. Here, Steve Ford, CEO of Parkinson’s UK, BIA’s Charity of the Year for 2018, explains how researchers are investigating new potential treatments for the disease and how initiatives from Parkinson’s UK are supporting and speeding up this process.

CEO Update Monday 9 April

We started off last week by seeing the highly anticipated launch of UKRI, marking a significant reorganisation of the UK funding landscape.

Video of the Week - BIO-Europe Spring 2018: J&J Innovation talks CNS partnering and Alzheimer's challenges

J&J Innovation's senior director of neuroscience innovation, Prof. John Isaac, talks to Scrip on the sidelines of the BIO-Europe Spring partnering meeting in Amsterdam about the unmet needs in neurology and the partnering approach J&J Innovation has for the development of new therapeutics for devastating neurodegenerative conditions such as Alzheimer's disease.